Seer, Inc. Replaces Dipchand Nishar with Meeta Gulyani to Fill Vacancy on the Audit Committee of the Board of Directors
January 24, 2022 at 06:09 am EST
Share
Seer, Inc. appointed Meeta Gulyani to fill a vacancy on the Audit Committee of the Board of Directors in connection with the resignation of Dipchand (Deep) Nishar from the Audit Committee. Mr. Nishar is not resigning from the Audit Committee as a result of any disagreement with the Company. The Board, including the Corporate Governance and Nominating Committee of the Board, determined that Ms. Gulyani qualifies as independent under the director independence standards set in the rules and regulations of the Securities and Exchange Commission and the applicable listing standards of the Nasdaq Stock Market and also satisfies the additional requirements of financial literacy and audit committee independence for audit committee service under the applicable rules and regulations of the SEC and the listing standards of Nasdaq.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
